<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679846</url>
  </required_header>
  <id_info>
    <org_study_id>2014-852</org_study_id>
    <nct_id>NCT02679846</nct_id>
  </id_info>
  <brief_title>Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SAVE is a stratified cluster-randomised controlled, parallel group, open-label trial, with
      Epileptic Monitoring Unit (EMU) as the units of randomisation and patients as the unit of
      analysis.

      The focus of research is the management of AntiEpileptic Drugs (AEDs) withdrawal during long
      term Video EEG (VEEG) monitoring in patients with drug resistant seizures. This
      non-standardised medical practice, which aims at promoting the occurrence of seizures during
      the time limit of the monitoring period, exposes patients to significant risks which should
      be minimised by harmonisation of practice and a standardised protocol of AEDs withdrawal.

      SAVE will assess the impact of a standardised protocol of AEDs withdrawal during long-term
      VEEG monitoring on the frequency of seizure-related serious adverse events occurring during
      these monitorings and on the ability to obtain VEEG recording of seizures within appropriate
      time limits.

      10 of the 22 EMUs will be randomised to the group where the standardised protocol of AEDs
      withdrawal will be used systematically, while the other ten EMUs will continue their current
      non-standardised practice of AEDs withdrawal, and will serve as a control group.

      The setting of the study will include a 6 months evaluation phase, prior to randomisation,
      during which the organisational characteristics, baseline EMUs' activity, current management
      of AEDs withdrawal, and rate of Serious Adverse Events (SAEs) of each participating center
      will be evaluated.

      The standardised study protocol of AEDs withdrawal has been defined on the basis of a
      systematic review of all relevant publications in the field.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who develop seizure-related serious adverse events during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
    <description>Proportion of patients who develop seizure-related serious adverse events during long-term VEEG monitoring, defined as the occurrence of one or more of the following events:
Convulsive or non-convulsive status epilepticus
4-hour seizure cluster (≥ 3 seizures / 4 hours)
secondarily generalised seizure unusual for the patient (≤ 1/year)
vertebral compression
other fracture (including broken tooth)
post-ictal psychosis
post-ictal aspiration pneumonia
cardio-respiratory arrest
Any other seizure-related serious injury or adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop each of the above seizure-related SAEs during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop SAEs unrelated to the occurrence of a seizure, during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who develop adverse events, including serious and non-serious adverse events, during long-term VEEG monitoring</measure>
    <time_frame>from date of inclusion until end of study (maximum 36 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay between onset of monitoring and VEEG recording of the first seizure (in hours)</measure>
    <time_frame>from date of inclusion until the first seizure (maximum 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in whom at least one seizure will be recorded during the VEEG monitoring</measure>
    <time_frame>from date of inclusion until the end of monitoring (maximum 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in whom the duration of VEEG monitoring will extend beyond its initially scheduled time limits</measure>
    <time_frame>from date of inclusion until the end of monitoring (maximum 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of VEEG</measure>
    <time_frame>from date of inclusion until the end of monitoring (maximum 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1440</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Standardized protocol of AEDs withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Centers will continue their current practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized protocol</intervention_name>
    <description>The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients</description>
    <arm_group_label>Standardized protocol of AEDs withdrawal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female suffering from drug-resistant epilepsy

          -  Age ≥ 6 years old

          -  Inpatient in one of the participating EMUs for recording seizure during long-term VEEG
             monitoring (≥ 48 hours)

          -  Patient who gave its written informed consent to participate to the study, or for
             children, whose minimum one of parents had given its written informed consent

        Exclusion Criteria:

          -  Age &lt; 6 years old

          -  Inpatient in one of the participating EMUs for performing short-term VEEG monitoring
             (&lt;48 hours)

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain RHEIMS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Neurologie Fonctionnelle et d'Epileptologie et Institut des Epilepsies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain RHEIMS, MD</last_name>
    <phone>4 72 35 70 44</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvain.rheims@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Laure CHARLOIS</last_name>
    <phone>4 72 11 80 70</phone>
    <phone_ext>+33</phone_ext>
    <email>anne-laure.charlois@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Berquin, MD</last_name>
      <phone>322668260</phone>
      <phone_ext>+33</phone_ext>
      <email>berquin.patrick@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Berquin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Ricard, MD</last_name>
      <phone>241355653</phone>
      <phone_ext>+33</phone_ext>
      <email>BrRicard-Mousnier@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Ricard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie N'Gyuen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital R. Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Montaudouin, MD</last_name>
      <phone>556795679</phone>
      <phone_ext>+33</phone_ext>
      <email>mdemontaudouin@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Montaudouin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital HFME</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis ARZIMANOGLOU, MD</last_name>
      <phone>427856047</phone>
      <phone_ext>+33</phone_ext>
      <email>Alexis.arzimanoglou@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis ARZIMANOGLOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital P. Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Rheims, MD</last_name>
      <phone>472357044</phone>
      <phone_ext>+33</phone_ext>
      <email>sylvain.rheims@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Rheims, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Isnard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Catenoix, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Montavont, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Général</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Lemesle, MD</last_name>
      <phone>380293754</phone>
      <phone_ext>+33</phone_ext>
      <email>martine.lemesle@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Martine Lemesle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Kahane, MD</last_name>
      <phone>476765448</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.kahane@ujf-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Kahane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorella Minotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Vercueil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Sabourdy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital R. Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Derambure, MD</last_name>
      <phone>320446373</phone>
      <phone_ext>+33</phone_ext>
      <email>Philippe.DERAMBURE@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Philippe Derambure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Willian Szurhaj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Vignal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Bartolomei, MD</last_name>
      <phone>491385833</phone>
      <phone_ext>+33</phone_ext>
      <email>fabrice.bartolomei@mail.ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice Bartolomei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès Trébuchon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aileen Mc Gonigal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Aubert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital G. de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arielle Crespel, MD</last_name>
      <phone>467337240</phone>
      <phone_ext>+33</phone_ext>
      <email>a-crespel@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Arielle Crespel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Gélisse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Maillard, MD</last_name>
      <phone>383852379</phone>
      <phone_ext>+33</phone_ext>
      <email>l.maillard@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Louis Maillard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre Vignal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Thomas, MD</last_name>
      <phone>492037896</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.p@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Bourg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Navarro, MD</last_name>
      <phone>142161813</phone>
      <phone_ext>+33</phone_ext>
      <email>vincent-navarro@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Navarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Dupont, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude Adam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kaminska, MD</last_name>
      <phone>144491585</phone>
      <phone_ext>+33</phone_ext>
      <email>anna.kaminska@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anna Kaminska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Taussig, MD</last_name>
      <phone>148036943</phone>
      <phone_ext>+33</phone_ext>
      <email>dtaussig@fo-rothschild.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine Taussig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martine Fohlen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane AUVIN, MD</last_name>
      <phone>140033667</phone>
      <phone_ext>+33</phone_ext>
      <email>stephane.auvin@rdb.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane AUVIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanina BELLAVOINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Biraben, MD</last_name>
      <phone>299284321</phone>
      <email>arnaud.biraben@univ-rennes1.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Biraben, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anca Paniscu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Ch. Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Lebas, MD</last_name>
      <phone>232888047</phone>
      <phone_ext>+33</phone_ext>
      <email>axel.lebas@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Axel Lebas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>St Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Convers, MD</last_name>
      <phone>473751667</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.convers@univ-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Convers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Mazzola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard Hirsch, MD</last_name>
      <phone>388116768</phone>
      <phone_ext>+33</phone_ext>
      <email>Edouard.hirsch@chu-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Edouard Hirsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Teppe</name>
      <address>
        <city>Tain</city>
        <zip>26602</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Petit, MD</last_name>
      <phone>475075956</phone>
      <phone_ext>+33</phone_ext>
      <email>jerome.petit@teppe.org</email>
    </contact>
    <investigator>
      <last_name>Jérôme Petit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viera Eid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Tourniaire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Valton, MD</last_name>
      <phone>561322643</phone>
      <phone_ext>+33</phone_ext>
      <email>VALTON.L@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Luc Valton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Denuelle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand De Toffol, MD</last_name>
      <phone>247478645</phone>
      <phone_ext>+33</phone_ext>
      <email>bertrand.detoffol@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand De Toffol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>withdrawal of antiepileptic drugs</keyword>
  <keyword>monitoring VEEG</keyword>
  <keyword>safety</keyword>
  <keyword>adverse event</keyword>
  <keyword>standardized protocol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

